Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study
Concurrent use of other investigational agents
Patients may not be receiving any other concurrent investigational agents, or have received any investigational agent within four weeks of commencing this protocol.
Concurrent therapy with any other investigational drug
Patients may not receive any concurrent investigational agents while on study
Concurrent use of any other investigational agents
Patients who are receiving concurrent investigational therapy;
Concurrent administration of any other investigational agents
Subject receiving concurrent chemotherapeutics or investigational agents within  days of study entry, including gliadel wafers or gliasite application.
Concurrent administration of other cancer specific therapy or investigational agents during the course of this study is not allowed
Concurrent treatment with any other investigational therapeutic agents
No other concurrent chemotherapeutic or investigational agents for this cancer. However, concurrent glucocorticoids are allowed;
Receiving concurrent investigational therapy
No other concurrent investigational agents are allowed
Concurrent use of other investigational agents
Patients receiving concurrent investigational chemotherapeutic agents
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents).
Patients receiving any concurrent investigational agents
Concurrent use of restricted agents
Concurrent enrollment on another investigational therapy
Concurrent use of other investigational agents or Optune device
Concurrent use of investigational therapeutic agent
Concurrent use of any other investigational agents
Concurrent use of investigational therapeutic agent
Subjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibited
Concurrent use of any other investigational agents
The use of other concurrent investigational agents will not be allowed
Concurrent use of other investigational agents
Concurrent use of any other investigational agents
Patients receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy
Concurrent administration of any other investigational agents
Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll  weeks after completion of prior agent)
Concurrent treatment with other investigational agents is not permitted
Concurrent therapy with any other investigational drug
Concurrent use of other investigational agents.
Concurrent treatment with other investigational drugs.
Patients may not receive any other concurrent investigational agents while on study
Concurrent treatment with other investigational agents
Concurrent anti-cancer treatment in another investigational trial
Concurrent use of investigational therapeutic agent
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) other than temozolomide
Concurrent use of any other investigational agents.
Use of investigational agents or concurrent anti-cancer treatment within the last  weeks of registration
Other concurrent investigational agents;
Concurrent therapy with other investigational agents
Concurrent anti-cancer treatment in another investigational trial
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
Concurrent use of other investigational agents
Concurrent therapy with any other investigational agent
ANY concurrent investigational agents
No concurrent methotrexate, thiotepa, cytarabine, or investigational agents
Concurrent use of other investigational agents and patients who have received investigational drugs =<  weeks prior to enrollment
Concurrent treatment with other investigational agents(s)
No other concurrent investigational treatment
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents, radiation or immunotherapy) within  weeks of the first dose of the study drug
Concurrent use of any other investigational agents on a clinical trial
No other concurrent investigational agents
Patients who are receiving any other investigational agents with the intent to treat myeloma; permitted concurrent therapies include:\r\n* Bisphosphonates
Concurrent use of other investigational agent
Patient is receiving concurrent treatment with other investigational agents not allowed as part of the combination regimen in the parental study protocol.
Concurrent enrollment in another investigational clinical study
Patients receiving concurrent investigational drugs
Concurrent investigational drugs
Concurrent use of investigational agents
Concurrent use of investigational therapeutic agent
Concurrent use of investigational therapeutic agent
Concurrent therapy with an investigational agent
Concurrent therapy with investigational agents
Concurrent systemic therapy for prostate cancer with investigational agents.
